A new prostate cancer medication shows promise in treating aggressive disease, according to a study.

A new study suggests that there may be a promising new strategy in combating aggressive forms of prostate cancer.

Scientists from Flinders University and the University of South Australia examined the potential of CDKI-73 to combat drug-resistant prostate cancer.

The study published in the British Journal of Cancer reportedly found that this drug "resists conventional treatments."

According to the American Cancer Society (ACS), prostate cancer is the second-leading cause of cancer death among American men, surpassed only by lung cancer.

According to the ACS, in 2024, approximately 299,010 new cases will be diagnosed and over 35,000 men will die from the disease.

According to Flinders University, the disease often develops into aggressive forms that do not respond to standard hormone treatments.

Professors Luke Selth and Shudong Wang, along with other researchers, focused on cyclin-dependent kinase 9 (CDK9) as a protein that promotes the growth and sustainability of prostate cancer cells.

Flinders University researcher Selth confirmed in a press release that the CDKI-73 inhibitor effectively blocks prostate cancer growth in models and tumor samples.

The research shows that CDKI-73 effectively inhibits the growth of prostate cancer, including aggressive subtypes that are resistant to existing treatments, he stated.

"Importantly, CDKI-73 targets cancer cells specifically without harming normal cells."

In an email to Planet Chronicle Digital, Selth stated that the drug is available as an oral tablet, which could aid in its use as a new treatment.

"We still need to do a lot more work to fully understand the potential of CDK9 inhibitors and to deliver a new treatment for patients."

Selth stated that the study findings represent a "significant advancement in comprehending CDK9's role in aggressive prostate cancer."

He added that although we have said that, a lot more work is needed to fully understand the potential of CDK9 inhibitors and to deliver a new treatment for patients.

Wang stated in the release that CDKI-73, which he developed, is a "promising candidate for treating solid tumors, including prostate cancer."

Our proof-of-principle study is crucial for future clinical trials, and our findings will guide future research on the effectiveness of CDKI-73 as a prostate cancer treatment.

Flinders University reports that CDKI-73 is currently being investigated in phase 2 clinical trials for patients with relapsed and therapy-resistant acute myeloid leukemia (AML), a type of blood cancer that affects the bone marrow and blood cells.

The research team plans to conduct additional trials to evaluate the effectiveness and safety of the drug before it is administered to patients, according to Wang.

For more Health articles, visit www.Planet Chronicle/health

Men aged 50 and above, as well as those over 40 with a family history of prostate cancer, should discuss prostate cancer screening with their providers during routine check-ups, according to Selth.

Dr. Marc Siegel, a clinical professor of medicine at NYU Langone Medical Center and a senior medical analyst for Planet Chronicle, provided his commentary on the drug's potential, despite not being involved in the study.

He informed Planet Chronicle Digital that CDK 9 is an enzyme linked to prostate cancer development.

"A CDKI-73 inhibitor was discovered to suppress growth and induce cell death in human prostate cancer cells, as well as in animals and models, according to a new study."

"Siegel stated that the drug has not been used in humans and clinical trials may be necessary. However, it shows potential in treating advanced or aggressive prostate cancer."

Planet Chronicle Digital reached out to oncologists for comment on the experimental drug.